Showing results (211-220 of 225) with videos related to

Sort By:
Pageof 23
BJU International|October 6, 2025
Temporal trends and clinical determinants of urinary diversion after radical cystectomyFrancesco Pellegrino, Mario de Angelis, Pietro Scilipoti, et al.
Urologia Internationalis|May 21, 2020
Urology in the Time of Coronavirus: Reduced Access to Urgent and Emergent Urological Care during the Coronavirus Disease 2019 Outbreak in ItalyAngelo Porreca, Michele Colicchia, Daniele D'Agostino, et al.
Journal of Clinical Medicine|July 13, 2024
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in ItalyMarino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Minerva Medica|October 8, 2024
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritisAlberto Lo Gullo, Simone Parisi, Andrea Becciolini, et al.
Therapeutic Advances in Musculoskeletal Disease|May 11, 2026
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort studySimone Parisi, Andrea Becciolini, Bernardo D'Onofrio, et al.
BJU International|June 20, 2020
The dramatic COVID 19 outbreak in Italy is responsible of a huge drop of urological surgical activity: a multicenter observational studyBernardo Rocco, Maria Chiara Sighinolfi, Marco Sandri, et al.
Rheumatology and Therapy|December 4, 2025
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter CohortEleonora Celletti, Myriam Di Penta, Alarico Ariani, et al.
Journal of Psoriasis and Psoriatic Arthritis|June 12, 2026
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et alCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 16, 2025
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter StudyCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Pageof 23